Press Esc to close

Welcome to Money Morning - Only the News You Can Profit From.

Close

This Says Our Favorite Biotech Is Off to the Races

Shares of a promising biotech we recommended back in February 2013 – jumped as much as 27% to a three-month high of $14.20 yesterday after the company said a new cancer drug met its main goal in a midstage clinical trial.

Its shares backtracked a bit as the day progressed but still closed 17.6% higher for the session. These shares have advanced 361% since we first told you about them. The stock has generated a peak gain of 456%, making it one of the 31 recommendations we’ve made to you that have doubled or better since we launched Private Briefing in August 2011. (More on that later…)

  • Why Uranium Prices Are at a Critical Tipping Point Thanks to considerably higher energy costs, the demand for nuclear power continues to rise.
    This year alone, 65 nuclear power plants are under construction, another 160 new reactors are currently in the planning stages, and 340 more have been proposed. Even Japan is now shifting its stance on nuclear power. According to Japan Today, newly elected Prime Minister Shinzo Abe now says he is willing to build new nuclear reactors.
    The demand for uranium is clearly going to be getting stronger, which presents a problem. There is already a uranium supply deficit of 40 million pounds a year.
    But supply and demand are only part of the uranium story... Read More...